Investigator Sponsored Studies

Supporting Investigator Research

Click Here to Apply

Alkermes seeks to support investigator research designed and conducted by independent clinicians and scientists. Alkermes has supported more than 40 clinical trials since the beginning of the ISS program in 2008. Alkermes can provide ARISTADA® & ARISTADA INITIO®, VIVITROL® and/or placebo to the ISS programs it supports. In addition, there may be limited financial support available. In general, the research we support is based in the U.S. with experienced researchers who have an established history of successfully receiving independent funding. If you have a “drug only” request and are seeking funding from a source outside Alkermes, we strongly recommend you submit a concept to Alkermes for review ahead of submitting your funding request.

Areas of Interest

Substance Use Disorders

  • Improving treatment initiation and adherence in AUD/OUD
  • Long-term treatment outcomes, including real world data in AUD/OUD
  • Neurologic profile of early recovery in OUD, including but not limited to sleep, cognition, and craving
  • Digital technologies for assessment of physiological parameters (e.g. wearables) and/or treatment access and outcomes (e.g. telehealth) in AUD/OUD
  • Implementing medication for AUD in healthcare systems


  • Reduction in social burden (e.g. family, treatment team) through use of LAIs
  • Demonstration of LAI benefits in specific comorbidities of schizophrenia (e.g. persistent substance problems) or subpopulations (e.g. persons with schizophrenia over the age of 60)
  • Short-term and long-term economic and clinical outcomes of LAI treatment in schizophrenia using real-world data
  • Outcomes research in schizophrenia and LAI use supporting continuity of care utilizing telehealth or other innovative technology-based approaches

ISS applications are reviewed by a cross functional team of medical and scientific staff to consider patient safety, operational feasibility, scientific merit, and alignment with Alkermes research goals and needs. Applications can be submitted in one of two ways:

Please be aware that Alkermes cannot guarantee support for ISS program applications and all decisions regarding such support will be made at Alkermes’ sole discretion. ISS submissions are accepted on a rolling submission basis.

Request for Proposals (RFPs)

Alkermes will announce a Request for Proposals (RFP) for research in key clinical areas where gaps in data have been identified. Each RFP will focus on areas where Alkermes support could potentially have the greatest impact on improved patient care and outcomes.

Grants awarded as a result of an RFP are awarded solely for the purpose of advancement of basic research or enhancement of disease understanding or clinical outcomes.

Please be aware that Alkermes cannot guarantee support for RFP program applications and all decisions regarding such support will be made at Alkermes’ sole discretion.

Concept proposals must be submitted to our online portal between the dates of July 1 – October 30, 2020.   Any concept proposal submitted after this period will not be eligible for RFP consideration.  

Concept proposals will be reviewed by the Alkermes ISS Committee, and applicants will be notified in November 2020 if they have been selected to submit a full protocol for further consideration.

ARISTADA® (aripiprazole lauroxil) & ARISTADA INITIO® (aripiprazole lauroxil) RFP Topics

Transition of Care
Use of LAIs in schizophrenia patients as they transition from higher levels of care or supervision to more independent care

Acute Care Setting
Feasibility and effectiveness of initiating an LAI in an acute care setting, such as intensive outpatient, ACT, crisis stabilization, or specialty psychiatric ER settings

Alcohol Use Disorder RFP Topic

Role of FDA-approved medications in the treatment of AUD, including:

  • The utilization in healthcare systems and associated treatment outcomes
  • Use in AUD patients with co-occurring mental health or substance use disorders

Submission Process

  • Requests must be submitted online at by the clinician or scientist
  • All submissions in response to an RFP should be in concept form.
  • Full proposals will be requested from select researchers once the initial review has been completed by the Alkermes ISS Committee
  • Reference the RFP # “2020-RFP-SCH” or “2020-RFP-AUD” in the title when submitting through the portal
  • Financial support for the RFPs below is limited to $300,000 USD, inclusive of indirect costs
  • Alkermes can provide ARISTADA® (aripiprazole lauroxil) & ARISTADA INITIO® (aripiprazole lauroxil), VIVITROL® (naltrexone for extended-release injectable suspension) and/or placebo as part of the RFP program

Please contact with questions on the program.